Souhaitez-vous accéder aux communiqués récents ?

Friedreich’s ataxia is a genetic, debilitating and life-shortening neuromuscular disease1Milestone highlights Biogen’s growing portfolio in rare diseases and focus on addressing unmet needs of...

ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD Patient...

Biogen Appoints Monish Patolawala to its Board of Directors

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patients Showed No Decline And 60% Showed Clinical...

In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function.First study of a tau targeting drug that shows reduction of aggregated tau...

Late-breaking Phase 1b data assesses the clinical outcomes of reducing tau in patients with early-stage Alzheimer’s diseaseAdditional late-breaking presentations from the CLARITY AD study explore...

TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United StatesFDA approval is based on a robust analytical, non-clinical and clinical data package comparing...

Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE,...

TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October...